Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 2/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.44 |
| ▸ | GPR3 | P46089 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4730316 | 0.83 | CBFB (0.50) | CBFBTGFBR1GRM5LMNAKDM4E | |
| SCHEMBL28209756 | 0.83 | CBFB (0.50) | CBFBTGFBR1GRM5LMNAKDM4E | |
| SCHEMBL1206412 | 0.83 | CBFB (0.50) | CBFBTGFBR1GRM5LMNAKDM4E | |
| SCHEMBL14116546 | 0.83 | MPL (0.55) | CBFBTGFBR1GRM5LMNAKDM4E | |
| SCHEMBL11272726 | 0.82 | ALOX5AP (0.50) | CBFBTGFBR1GRM5LMNAKDM4E | |
| SCHEMBL5331896 | 0.82 | NPC1 (0.53) | CBFBTGFBR1GRM5CCR1CCR5 | |
| SCHEMBL996983 | 0.82 | CBFB (0.49) | CBFBTGFBR1GRM5KDM4ETRPV1 | |
| SCHEMBL24363083 | 0.79 | KDM4E (0.54) | CBFBTGFBR1GRM5LMNAKDM4E | |
| SCHEMBL4728125 | 0.79 | CBFB (0.49) | CBFBTGFBR1GRM5LMNAKDM4E | |
| SCHEMBL5990281 | 0.79 | KDM1A (0.50) | CBFBTGFBR1GRM5LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6890937-B2 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION (US) | 2005-05-10 | — | — | US | disclosed |
| US-6750233-B2 | SELECTIVITY | PHARMACIA CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-20040048852-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-03-11 | — | — | US | disclosed |
| US-6541489-B1 | Excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP- 1 | G. D. SEARLE & COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020177588-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2002-11-28 | — | — | US | disclosed |
| US-20010039287-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | PHARMACIA CORPORATION | 2001-11-08 | — | — | US | disclosed |
| US-20010014688-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | BARTA THOMAS E (US) | 2001-08-16 | — | — | US | disclosed |
| EP-1042290-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999025687-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177588-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP13, MMP9, MMP10 | CBFB 2918/4885TGFBR1 857/4885GPR3 4244/4885 |
| US-20010039287-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | MMP13, MMP9, MMP10 | CBFB 2918/4885TGFBR1 857/4885GPR3 4244/4885 |
| US-20040048852-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP9, MMP1, MMP13 | CBFB 3749/4885TGFBR1 183/4885GPR3 2609/4885 |
| US-20010014688-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | MMP13, MMP9, MMP10 | CBFB 2918/4885TGFBR1 857/4885GPR3 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.